ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,00%
Dow Jones
38 686,32
1,51%
DAX
18 483,07
0,00%
Brent Oil
81,095
0,36%
Bitcoin
69 067,47
1,95%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Nevro Corp (NVRO)

  7. Nevro Corp (NVRO) Actualités

NVRO

Nevro (NVRO)

Nevro Corp
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:NVRO
DateHeureSourceTitreSymboleSociété
30/05/202423h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVRONevro Corp
29/05/202422h21Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVRONevro Corp
24/05/202422h15PR Newswire (US)Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08NYSE:NVRONevro Corp
17/05/202422h40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NVRONevro Corp
09/05/202422h05PR Newswire (US)Nevro to Present at BofA Securities 2024 Healthcare ConferenceNYSE:NVRONevro Corp
07/05/202422h56Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NVRONevro Corp
07/05/202422h05PR Newswire (US)Nevro Reports First-Quarter 2024 Financial ResultsNYSE:NVRONevro Corp
17/04/202414h30PR Newswire (US)Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024NYSE:NVRONevro Corp
28/02/202422h10PR Newswire (US)Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNYSE:NVRONevro Corp
23/02/202423h08Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:NVRONevro Corp
21/02/202422h06PR Newswire (US)Nevro Enters Into Cooperation Agreement With Engaged CapitalNYSE:NVRONevro Corp
21/02/202422h05PR Newswire (US)Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNYSE:NVRONevro Corp
14/02/202421h47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNYSE:NVRONevro Corp
01/02/202422h30PR Newswire (US)Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic NeuropathyNYSE:NVRONevro Corp
29/01/202422h30PR Newswire (US)Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024NYSE:NVRONevro Corp
18/01/202422h15PR Newswire (US)Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic NeuropathyNYSE:NVRONevro Corp
17/01/202422h15PR Newswire (US)Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual MeetingNYSE:NVRONevro Corp
11/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:NVRONevro Corp
10/01/202423h26Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NYSE:NVRONevro Corp
09/01/202414h30PR Newswire (US)Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue ResultsNYSE:NVRONevro Corp
04/01/202422h15PR Newswire (US)Nevro to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:NVRONevro Corp
11/12/202315h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNYSE:NVRONevro Corp
30/11/202323h19PR Newswire (US)Nevro Announces Acquisition of Vyrsa™ TechnologiesNYSE:NVRONevro Corp
20/11/202313h00PR Newswire (US)Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back PainNYSE:NVRONevro Corp
01/11/202321h01PR Newswire (US)Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 GuidanceNYSE:NVRONevro Corp
04/10/202313h00PR Newswire (US)Nevro to Report Third Quarter 2023 Financial ResultsNYSE:NVRONevro Corp
18/09/202313h00PR Newswire (US)New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation TherapyNYSE:NVRONevro Corp
23/08/202313h00PR Newswire (US)Nevro Announces Participation in Upcoming Investor ConferencesNYSE:NVRONevro Corp
16/08/202313h00PR Newswire (US)New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic NeuropathyNYSE:NVRONevro Corp
10/08/202310h52PR Newswire (US)Nevro announces launch of HFX Connect™ in Europe and CE marking of expanded labelling for the HFX™ SCS system.NYSE:NVRONevro Corp
 Showing the most relevant articles for your search:NYSE:NVRO

Dernières Valeurs Consultées

EU
PX4
SBF 120
EU
HO
Thales
EU
RI
Pernod Ricard
EU
BEL20
Bel 20
EU
AF
Air FranceKLM
NASDAQ
AAPL
Apple
EU
DG
Vinci
NASDAQ
MSFT
Microsoft
EU
VIV
Vivendi
NASDAQ
AMZN
Amazon.com
EU
RNO
Renault
EU
CS
Axa
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés